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Parabrachial nucleus Slow-delta oscillations occur with the administration of high-dose (concentration >60% and total gas
ﬂow rate >4 liters per minute) nitrous oxide.
 Our ﬁndings are in contrast to the beta oscillations commonly observed with lower concentrations
(20–40%) of nitrous oxide.
 These slow-delta oscillations may result from nitrous oxide-induced blockade of major excitatory
inputs (NMDA glutamate projections) from the brainstem to the thalamus and cortex.
a b s t r a c t
Objectives: Switching from maintenance of general anesthesia with an ether anesthetic to maintenance
with high-dose (concentration >50% and total gas ﬂow rate >4 liters per minute) nitrous oxide is a
common practice used to facilitate emergence from general anesthesia. The transition from the ether
anesthetic to nitrous oxide is associated with a switch in the putative mechanisms and sites of anesthetic
action. We investigated whether there is an electroencephalogram (EEG) marker of this transition.
Methods: We retrospectively studied the ether anesthetic to nitrous oxide transition in 19 patients with
EEG monitoring receiving general anesthesia using the ether anesthetic sevoﬂurane combined with
oxygen and air.
Results: Following the transition to nitrous oxide, the alpha (8–12 Hz) oscillations associated with
sevoﬂurane dissipated within 3–12 min (median 6 min) and were replaced by highly coherent
large-amplitude slow-delta (0.1–4 Hz) oscillations that persisted for 2–12 min (median 3 min).
Conclusions: Administration of high-dose nitrous oxide is associated with transient, large amplitude
slow-delta oscillations.
Signiﬁcance: We postulate that these slow-delta oscillations may result from nitrous oxide-induced
blockade of major excitatory inputs (NMDA glutamate projections) from the brainstem (parabrachial
nucleus and medial pontine reticular formation) to the thalamus and cortex. This EEG signature of
high-dose nitrous oxide may offer new insights into brain states during general anesthesia.
 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Use of nitrous oxide dates back to the early 1800s, making it the
oldest anesthetic currently administered (Andrews, 1868). Becauseadministration of nitrous oxide alone is not sufﬁciently potent to
produce general anesthesia, today it is usedmost often as an adjunct
during general anesthesia to reduce the quantity administered and
hence, the side effects of the potent ether anesthetics. For example,
use of nitrous oxidewith ether anesthetics, such as sevoﬂurane, des-
ﬂurane or isoﬂurane, in combination with an oxygen and air mix-
ture, a muscle relaxant and analgesics is a standard anesthetic
combination (Eger et al., 1997). During closure of the surgical inci-
sion, a common practice is to switch from the ether anesthetic to
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Administration of high concentration nitrous oxide (>50% with
40% oxygen) at high ﬂow rates causes its rapid uptake in the lungs,
circulation and the brain. At the same time, stopping the ether anes-
thetic terminates its steady statewithin the brain and the lungs, and
shifts its gradient towards removal. The switch from the ether anes-
thetic to nitrous oxide shifts the anesthetic state frommaintenance
of unconsciousness sufﬁcient for surgery to a state of sedation from
which a patient can be more rapidly awakened.
The sedative effects of nitrous oxide are believed to be mediated
through blockade of N-methyl-D-aspartate (NMDA) glutamatergic
receptors (Jevtovic-Todorovic et al., 1998; Mennerick et al., 1998;
Hemmings et al., 2005). The electroencephalogram (EEG) under
nitrous oxide is commonly associated oscillations in the beta
(12–25 Hz) and the gamma (>25 Hz) ranges and possibly a
decrease in power in the delta (1–4 Hz) range (Yamamura et al.,
1981). Recently, it has been reported that at inspired concentra-
tions of 40%, nitrous oxide actually maintains activity in the beta
and gamma bands while reducing activity in the delta (1–4 Hz)
and in the theta (5–8 Hz) bands (Foster and Liley, 2011, 2013).
The link between the actions of nitrous oxide at glutamatergic
synapses and its EEG pattern has not been clearly established.
Characterizing the EEG activity of nitrous oxide concentrations
higher than 40% proved challenging because the higher concentra-
tions induced signiﬁcant nausea and emesis (Foster and Liley,
2011).
The EEG observed during the administration of ether anesthetics
shows large alpha, theta and slow-delta 0.1–4 Hz oscillations when
patients are sufﬁciently unconscious to conduct surgery (Akeju
et al., 2014; Brown et al., 2014). Because these patterns are similar
to those seen with propofol and given that both the ether anesthet-
ics and propofol (Feshchenko et al., 2004; Cimenser et al., 2011;
Purdon et al., 2013) are known to act at c-aminobutyric acid A
(GABAA) receptors, it is likely that the EEG patterns for the ether
anesthetics are related to the same GABAergic circuit mechanisms
as propofol (Bai et al., 1999; Hemmings et al., 2005; Ching et al.,
2010; Cimenser et al., 2011; Purdon et al., 2013). It has been
reported that the transition from an ether anesthetic to high-dose
nitrous oxide is marked by EEG slow-delta oscillations rather than
by beta and gamma oscillations (Hagihira et al., 2012). The differ-
ences in the EEG signatures between the ether anesthetic,
low-dose nitrous oxide and high-dose nitrous oxide suggest that
there may be different mechanisms and sites of anesthetic action
in the three cases. Therefore, we investigated the ether anesthetic
to nitrous oxide transition using spectral analysis to develop a
detailed quantitative assessment of the EEG signatures associated
with high-dose nitrous oxide.
We studied retrospectively the ether anesthetic to high-dose
nitrous oxide transition in 19 patients receiving sevoﬂurane, oxy-
gen and air for maintenance of general anesthesia. We report that
high-dose nitrous oxide is associated with the disappearance of
oscillations from 5 Hz and above over 3–12 min and the appear-
ance of large amplitude, highly coherent slow (0.1–1 Hz) and delta
(1–4 Hz) oscillations. The slow-delta oscillations persist for 2–
12 min and then transition to high-frequency, low-amplitude beta
and gamma oscillations. We propose transient blockade of gluta-
matergic inputs from the brainstem to the thalamus and to the
basal forebrain as a neural circuit mechanism for this EEG signa-
ture associated with high-dose nitrous oxide administration.
2. Materials and methods
2.1. Study protocol
This retrospective observational study was approved by the
Human Research Committee at Massachusetts General Hospital.We reviewed our database of 954 cases of general anesthesia and
simultaneous EEG recordings collected between September 1,
2011 and October 30, 2014. We identiﬁed 169 cases in which
sevoﬂurane and nitrous oxide were administered. From these we
removed 68 cases in which the patients had received sevoﬂurane
and nitrous oxide as their entire anesthetic. Of the remaining 101
cases, we identiﬁed 26 cases that met the criteria of general anes-
thesia maintenance with sevoﬂurane and oxygen with a conver-
sion to nitrous oxide at a concentration >50% during skin closure.
Of the 26 cases, we removed 7 cases: 4 cases due to train-of-four
monitor artifacts, and 3 cases due to incomplete EEG records.
Therefore, we chose for analysis 19 cases, involving 19 different
patients. Table 1 summarizes the patient characteristics.
For all 19 patients, anesthetic concentrations, oxygen delivery,
heart rate, blood pressure, and oxygen saturation were automati-
cally recorded in the electronic medical record (MetaVision,
Dedham, MA) at 1 min intervals. Intravenous drug doses and times
were recorded by the anesthesia caregivers. General anesthesia was
induced with propofol (mean ± standard deviation; 184 ± 48 mg)
and intubation was carried out using succinylcholine, cisatracurium,
vecuronium or rocuronium for muscle relaxation. General
anesthesia was maintained with sevoﬂurane, oxygen and air along
with either intravenous narcotics (17 cases), or paravertebral block
using local anesthetics and/or opioids (2 cases). Muscle relaxation
was maintained with cisatracurium, vecuronium or rocuronium.
Themaintenance concentration of expired sevoﬂurane ranged from
1.3% to 2.4% (median 1.7%). Air was added to the ﬂow of oxygen to
maintain a 40–80% fraction of inspired oxygen. During mainte-
nance, the total gas ﬂow was maintained between 0.9 and 8.0 liters
per minute (median 1.8 liters per minute) up through fascial
closure. For skin closure, total gas ﬂow was maintained between
2.0 and 14.0 liters per minute (median 5.7 liters per minute), the
maximum expired concentration of nitrous oxide achieved was
51–79% (median 70%) and the sevoﬂurane concentration was
decreased to 1% or less. At case completion, sevoﬂurane and nitrous
oxide were discontinued and 100% oxygen was administered, typi-
cally at 8 liters perminute or higher to allow the patients to emerge.
2.2. EEG recordings and statistical analysis
The EEG was continuously recorded in each patient during gen-
eral anesthesia using the Sedline monitor (Masimo, Irvine, CA)
with the standard six-electrode frontal montage. The standard
Sedline Sedtrace electrode array records from electrodes located
approximately at positions Fp1, Fp2, F7, and F8, with ground elec-
trode at Fpz and reference electrode approximately 1 cm above
Fpz. Electrode impedance was less than 5 kX in each channel.
We report here the analyses using Fp1. The analyses were identical
for Fp1 and Fp2. The EEG recording began 3–5 min prior to induc-
tion of general anesthesia and was continued brieﬂy after
extubation.
To compare the EEG differences between the sevoﬂurane and
nitrous oxide states, we identiﬁed from each patient’s electronic
medical record two representative periods, each 60-s in duration.
To represent steady-state sevoﬂurane general anesthesia, we chose
a 60-s EEG period beginning 15 min prior to the initiation of
nitrous oxide. For each subject, we identiﬁed the slow-delta oscil-
lation onset and offset times. We chose a period that was represen-
tative of the nitrous oxide effect by taking a 60-s segment,
beginning 30-s after the onset of the slow-delta oscillation. We also
computed the total cumulative dose of nitrous oxide to relate the
slow-delta oscillation appearance to the dose of nitrous oxide
received by the patient.
For each patient, we plotted the time-domain EEG signal. We
used standard multitaper spectral methods (Percival and Walden,
1993; Babadi and Brown, 2014) implemented in the Chronux
Table 1
Patient characteristics.
Patient Age
(years)
Sex Height
(cm)
Weight
(kg)
Surgical procedure Length of surgical procedure
(min)
Paravertebral
block = B
none = N
A 48 F 155 75 Mastopexy with augmentation, bilateral 583 N
B 44 F 165 79 Bilateral mastectomy with bilateral implant 313 B
C 22 F 168 118 Laparoscopic appendectomy 85 N
D 50 F 168 81 Abdominoplasty 268 N
E 63 M 178 108 Kidney transplant 266 N
F 70 F 157 53 Laparoscopic distal pancreatectomy 196 B
G 61 F 163 77 Laparoscopic transverse colectomy 261 N
H 54 F 178 111 Laparoscopic cholecystectomy 105 N
I 47 F 178 85 Total abdominal hysterectomy 181 N
J 65 M 170 94 Thyroidectomy 378 N
K 56 F 160 103 Thyroidectomy total 196 N
L 81 F 152 72 Left mastectomy with sentinel node biopsy 101 N
M 62 F 160 68 Laparoscopic sigmoid colectomy; liver biopsy 162 N
N 37 F 160 82 Abdominoplasty 218 N
O 37 F 157 64 Abdominoplasty 179 N
P 75 M 178 75 Laparoscopic esophageal hernia repair 191 N
Q 69 F 163 66 L mastectomy simple 137 N
R 34 F 173 61 Lap myomectomy 194 N
S 38 M 188 98 Kidney transplant 210 N
Mean (sd) 53 (16) M = 4
F = 15
167 (10) 83 (18) 222 (114) B = 2
N = 17
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and Bokil, 2008). The spectrogram is the decomposition of the
EEG signal into its spectral components (power by frequency)
across time, where power is the log base 10 of the EEG signal
amplitude squared. The parameters for the multitaper spectral
analysis were: window length T = 2s with no overlap,
time-bandwidth product TW = 3, number of tapers K = 5, and spec-
tral resolution of 3 Hz. We computed group-level spectrograms for
the sevoﬂurane and the nitrous oxide periods by taking the median
spectrogram across all patients in each period.
We conducted for each patient a coherence analysis in the
sevoﬂurane and the nitrous oxide periods using the multitaper set-
tings chosen to compute the spectra (Mitra and Bokil, 2008). The
coherence is the correlation between two EEG signals at a given
frequency which we computed as the magnitude of the
cross-spectrum between the two signals divided by the square root
of the product of the spectra of the two signals. We chose the fron-
tal EEG electrodes, F7 and F8, to compute coherence during the
sevoﬂurane and the nitrous oxide periods (Percival and Walden,
1993). We calculated the coherence between F7 and F8 because
these electrodes have greater spatial separation than electrodes
Fp1 and Fp2.
To analyze the difference in power (coherence) between the
sevoﬂurane period and the nitrous oxide period we computed
within subject the difference in power (coherence) between the
two anesthetic states in three frequency bands: slow-delta (0.1–
4 Hz), alpha (8–12 Hz) and beta-gamma (13–40 Hz). We estimated
the difference in the spectral properties of the two anesthetic
states across the 19 patients by computing the median difference
in power (coherence) in each frequency band and the 95% conﬁ-
dence interval for the true median. We use the median in our anal-
yses because the sample has only 19 patients. The median provides
a robust, nonparametric estimate of the magnitude of the differ-
ence and the 95% conﬁdence intervals provide a conservative esti-
mate of the uncertainty in the difference (Mosteller and Rourke,
1973). Because each comparison involved making an inference
about a median power difference in a frequency band, we consid-
ered a result to be statistically signiﬁcant if the 95% conﬁdence
interval did not contain 0. Because there are 19 patients, the cover-
age probability for the 95% conﬁdence intervals was at least, 0.98
instead of 0.95.3. Results
3.1. Spectral analysis of the sevoﬂurane to nitrous oxide transition
Several minutes were required for both the decrease in the
sevoﬂurane concentration (Fig. 1, upper subpanels, blue curves)
and the increase in the nitrous oxide concentration (Fig. 1, upper
subpanels, red curves) to reach the target levels. For example,
Patient A (Fig. 1A) required 7 min to both reach the target nitrous
oxide concentration and for the sevoﬂurane concentration to reach
1% or less. In contrast, Patient C (Fig. 1C) required 4 min to reach
the target nitrous oxide concentration and 7 min to achieve the
sevoﬂurane decrease. The median time to achieve a 50% expired
nitrous oxide target concentration was 3 min with a range of 2–
16 min, whereas the median time to decline to 1% expired sevoﬂu-
rane or less was 3 min with a range of 1–20 min. During the tran-
sition, spectral power in the alpha band dissipated (Fig. 1 and
Supplementary Fig. S1, middle subpanels). This was followed by
a substantial decrease in power across all frequencies above 5 Hz
with a concomitant substantial increase in the slow-delta power
(Fig. 1 and Supplementary Fig. S1, middle subpanels). The dramatic
differences in the raw EEG traces before and after administration of
nitrous oxide are illustrated in the lower subpanels of Fig. 1 and
Supplementary Fig. S1. The time required for the appearance of
the slow-delta oscillations and the disappearance of the alpha
oscillations was 3–12 min (median 6 min). The slow-delta oscilla-
tions persisted for 2–12 min (median 3 min) and then transformed
eventually into higher frequency beta-gamma (13–40 Hz) oscilla-
tions (Fig. 1 middle subpanels A–F, Supplementary Fig. S1 middle
subpanels G–S).
To display the groupdifference in spectral dynamics between the
sevoﬂurane and nitrous oxide periods, we computed across patients
the median spectrogram for the two periods (Fig. 2A and B). The
median spectrogramof the sevoﬂuraneperiod (Fig. 2A) showed sub-
stantial power in the alpha and slow-delta frequency bands. In con-
trast, the median spectrogram of the nitrous oxide period showed
greater power in the slow-delta frequency range, and less power
in the alpha frequency range comparedwith themedian sevoﬂurane
spectrogram (Fig. 2B). There was substantially less power at all fre-
quencies above 5 Hz in the median nitrous oxide spectrogram
(Fig. 2B) relative to the median sevoﬂurane spectrogram (Fig. 2A).
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Fig. 1. Time courses of anesthetic concentrations (upper subpanels); spectrograms (middle subpanels); and the time-domain signature of sevoﬂurane and the time-domain
signature of nitrous oxide-induced slow-delta oscillations (lower subpanels) for Patients A–F. The start of nitrous oxide and the decrease of sevoﬂurane are indicated by the
black dashed vertical line. The time courses of the anesthetic concentrations, sevoﬂurane (blue curve) and nitrous oxide (red curve), are shown in the upper subpanels. The
spectrograms (middle subpanels) during the sevoﬂurane period show large oscillations in the alpha frequency band (8–12 Hz) that dissipate with the transition to nitrous
oxide. After the nitrous oxide concentration plateaus, the spectrograms show increased power in the slow-delta frequency band (0.1–4 Hz) that persists for several minutes.
Ten-second EEG traces recorded during the sevoﬂurane period (*) and during the midpoint of the nitrous oxide-induced slow-delta oscillation period () are shown in the
lower subpanels. Slow-delta oscillations are present in both periods. However, the slow-delta oscillations are signiﬁcantly enhanced after the transition to nitrous oxide (See
Fig. 2D). The vertical line in panel F (min 5) is either an electrocautery or movement artifact.
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two periods we computed for each patient the average spectrum
(average of 30 spectra computed in 2-s windows) in each period.
We computed the group-level summary within each period as
the median of the average spectrum across subjects (Fig. 2C). For
the sevoﬂurane period, the median EEG power in the alpha band
was 2.6 dB [0.96 dB, 3.54 dB 95% conﬁdence interval], whereas
the median EEG power in the slow-delta band was 7.82 dB
[4.73 dB, 9.01 dB]. For nitrous oxide, the EEG power in the alpha
band was 8.64 dB [10.69 dB, 6.65 dB], whereas the EEG power
in the slow-delta band was 13.71 dB [10.50 dB, 15.99 dB] (Fig. 2C).
To make inferences about the power changes between the
sevoﬂurane and the nitrous periods we computed the spectra for
the two periods and analyzed the median difference in power in
three speciﬁc bands across subjects (Fig. 2D). The median differ-
ence (nitrous oxide – sevoﬂurane) in slow-delta power (Fig. 2D, tri-
angle) was 5.89 dB [5.77 dB, 6.98 dB]. The median difference in
alpha power (Fig. 2D, square) and in power in the beta-gamma
range (Fig. 2D, diamond) were respectively, 11.24 dB
[15.16 dB, 8.94 dB] and 8.82 dB [9.76 dB, 6.38 dB]. Each
difference in power was statistically signiﬁcant as none of the
95% conﬁdence intervals covered zero (denoted by * in Fig. 2D).3.2. Coherence analysis of the sevoﬂurane to nitrous oxide transition
We computed across patients the median coherence during the
sevoﬂurane period (Fig. 3A, blue curve) and during the nitrousA B
C D
Fig. 2. Group-level spectral analysis during the sevoﬂurane period, deﬁned as the 1-mi
period deﬁned as the 1-min segment around the midpoint of the slow-delta oscillation p
slow-delta and alpha frequency bands. (B) Median spectrogram during the nitrous oxide
power above 5 Hz compared with the sevoﬂurane period. (C) Median spectra for the sevo
frequency band for nitrous oxide is greater than that for sevoﬂurane. (D) Median differen
the slow-delta (triangle), alpha (square), and beta-gamma (diamond) ranges. All three
conﬁdence intervals covers zero.oxide period (Fig. 3A, red curve). The group-level coherence of
the sevoﬂurane period was strong in the slow-delta and alpha fre-
quencies. During the sevoﬂurane period (Fig. 3A, blue curve) the
alpha oscillation coherence was 0.61 [0.52, 0.66] and the
slow-delta oscillation coherence was 0.57 [0.53, 0.60]. In contrast,
the nitrous oxide period (Fig. 3A, red curve) showed a strong coher-
ence only in the slow-delta frequency range which was 0.65 [0.58,
0.80].
The median differences (nitrous oxide – sevoﬂurane) in coher-
ence were: 0.09 [0.04, 0.16] for the slow-delta band (Fig. 3B, trian-
gle); 0.08 [0.20, 0.03] for the alpha band (Fig. 3B, square); and
0.02 [0.01, 0.06] for the beta-gamma band (Fig. 3B, diamond). The
95% conﬁdence intervals for the median differences in coherence
did not cover zero for the slow-delta and alpha bands indicating
that these changes were statistically signiﬁcant (denoted by * in
Fig. 3B).
These results show that the transition to nitrous oxide from
sevoﬂurane is marked by a substantial decrease in alpha power,
a substantial increase in slow-delta power, a substantial decrease
in beta-gamma power, loss of coherence in the alpha band, and
enhanced coherence in the slow-delta band.4. Discussion
Nitrous oxide is most commonly associated with increased beta
and gamma oscillations (Yamamura et al., 1981) and more
recently, with maintenance of beta and gamma oscillations andn segment, 15 min prior to the start of nitrous oxide, and during the nitrous oxide
eriod. (A) Median spectrogram during the sevoﬂurane period, showing power in the
period, showing increased power in the slow-delta frequency band and decreased
ﬂurane (blue) and nitrous oxide (red) periods showing the power in the slow-delta
ce in power (nitrous oxide – sevoﬂurane) and 95% conﬁdence intervals computed in
power differences are statistically signiﬁcant (denoted by *) as none of the 95%
A B
Fig. 3. Group-level coherence analysis during the sevoﬂurane and during the nitrous oxide periods. (A) Median coherence during the sevoﬂurane (blue) and during the
nitrous oxide (red) periods. (B) Median differences in coherence (nitrous oxide – sevoﬂurane) and 95% conﬁdence intervals computed in the slow-delta (triangle), alpha
(square), and beta-gamma (diamond) ranges. The coherence differences in the slow-delta and in the alpha bands are statistically signiﬁcant (denoted by *) as none of the 95%
conﬁdence intervals cover zero.
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2013). These studies used concentrations of nitrous oxide between
20% and 40%. Our ﬁndings give insight into the EEG dynamics
induced by the higher nitrous oxide concentrations of 50–70%
administered at high ﬂow. We have demonstrated that switching
from sevoﬂurane to nitrous oxide is associated with slow-delta
oscillations. These slow-delta oscillations begin approximately
6 min after the switch and last from 3 to 12 min, before changing
to the beta and gamma oscillations typically associated with
nitrous oxide (Yamamura et al., 1981; Foster and Liley, 2011,
2013). The transition to nitrous oxide from sevoﬂurane is marked
by a substantial decrease in alpha power, a substantial increase
in slow-delta power, substantial decrease in beta-gamma power,
and loss of coherence in the alpha band and enhanced coherence
in the slow-delta band. Slow-delta oscillations have been reported
when a 50:50 mixture of nitrous oxide and oxygen is administered
at 2 atmospheres (Faulconer et al., 1949). Slow-delta oscillations
have been reported in the transition from halothane, an alkane
anesthetic to nitrous oxide (Avramov et al., 1990), as well as in
the transition from the ether anesthetic, isoﬂurane to nitrous oxide
(Hagihira et al., 2012). In both cases, the slow-delta oscillations
were transient. Avramov and colleagues reported principally
time-domain analyses, whereas Hagihira and colleagues used their
own biocoherence-based index to conduct their analyses. Neither
research group proposed a neural circuit hypothesis to explain
these observations.4.1. A putative mechanism of nitrous oxide-induced slow-delta
oscillations
The mechanism of these slow-delta oscillations could be due to
rapid delivery of high-dose (high concentrations at high ﬂows)
nitrous oxide to subcortical circuits and subsequent action of
nitrous oxide at NMDA glutamate targets in major subcortical sites
(Fig. 4). A putative subcortical target is the thalamus and the
NMDA-mediated glutamatergic projections it receives from the
parabrachial nucleus and from the medial pontine reticular forma-
tion, both of which lie in the pons (Boon and Milsom, 2008; Fuller
et al., 2011) (Fig. 4A). A second putative subcortical target is the
basal forebrain and the glutamatergic projections it receives from
the parabrachial nucleus. (Moga et al., 1990). These are theprincipal glutamatergic arousal pathways emanating from the
brainstem (Saper and Loewy, 1980; Fulwiler and Saper, 1984;
Fuller et al., 2011; Kaur et al., 2013). When nitrous oxide is admin-
istered at high dose, it is taken up by the arterial circulation in the
lungs. Blood containing the high nitrous oxide concentration
reaches the brain through the internal carotid arteries bilaterally
and the basilar artery posteriorly. This high dose of nitrous oxide
reaches the thalamus via the thalamotuberal artery, the thalamop-
erforant artery, the thalamogeniculate artery, the anterior choroi-
dal artery and the medial and lateral posterior choroidal arteries
(Biller, 2009). The thalamotuberal artery arises from the posterior
communicating artery; the thalamoperforant artery arises from
the basilar artery; the thalamogeniculate artery arises from the
posterior cerebral artery; the anterior choroidal artery arises from
the internal carotid; and the medial and later posterior choroidal
arteries arise from the posterior cerebral artery (Biller, 2009).
Nitrous oxide reaches the basal forebrain from the anterior com-
municating arteries which arise from the middle cerebral artery
(Biller, 2009).
Based on this neural circuitry and vascular anatomy, the
slow-delta oscillations could be produced as follows. Delivery of
a high-dose nitrous oxide could lead to an intense blockade of
these major NMDA-glutamatergic excitatory pathways from the
parabrachial nucleus and the medial pontine reticular formation
to the thalamus and basal forebrain (Fig. 4B). Such a blockade
would in turn produce decreased excitatory inputs from the thala-
mus to the cortex and from the basal forebrain to the cortex. As we
discuss below, removal of substantial subcortical excitatory inputs
to the cortex has been commonly associated with the production of
EEG slow-delta oscillations.4.2. Slow-delta oscillations in other brain states
Frédéric Bremer ﬁrst demonstrated in the 1930s that slow-delta
oscillations could be produced by removing signiﬁcant brainstem
inputs to the cortex (Posner et al., 2007). In cats, he showed that
transection of the brainstem at the level of the midbrain resulted
in EEG slow-delta and spindle oscillations, whereas transection of
the brainstem at the level of intersection between the spinal cord
and the medulla resulted in the persistence of active,
awake-appearing EEG patterns. He termed the former pattern
AB
Fig. 4. Putative neurophysiological mechanisms of nitrous oxide-induced slow-delta oscillations. (A) The parabrachial nucleus (PB) and the medial pontine reticular
formation (mPRF) provide excitatory glutamatergic (Glu) projections to the basal forebrain and to the central thalamus. (B) Delivery of a high concentration of nitrous oxide
(N2O) likely leads to an intense blockade of these major N-methyl-D-aspartate (NMDA) glutamatergic excitatory pathways from the PB and the mPRF to the thalamus and
basal forebrain. This results in decreased excitatory inputs from the thalamus and the basal forebrain to the cortex that could contribute to the production of slow-delta
oscillations.
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2007). Slow-wave sleep, deﬁned by its associated slow-wave and
delta EEG patterns, is believed to result in part from the activation
of GABA- and galanin-mediated inhibitory projections from the
pre-optic area of the hypothalamus to the arousal centers in the
midbrain pons and hypothalamus (Saper et al., 2005). Similarly,
slow-delta oscillations and concomitant unconsciousness due to
complex partial seizures originating in the temporal lobe have
been linked to inhibition of thalamic, basal forebrain and brain-
stem arousal circuits (Norden and Blumenfeld, 2002; Englot
et al., 2010).
Slow and delta oscillations are also produced by other anesthet-
ics. Bolus administration of propofol to induce general anesthesia
yields EEG slow-delta oscillations that appear within 20–30 s and
are associated with loss of consciousness (Lewis et al., 2012). The
mechanism of these slow waves is most likely GABAergic inhibi-
tion by propofol at the synapses of the pre-optic area projections
onto the brainstem arousal centers producing decreased excitatory
inputs to the cortex (Brown et al., 2010, 2011). Maintenance of
unconsciousness with propofol is characterized by both alpha
and slow-delta oscillations (Feshchenko et al., 2004; Cimenser
et al., 2011; Lewis et al., 2012; Purdon et al., 2013). The EEG alpha
oscillations are hypersynchronous across the front of the scalp andare believed to require GABAergic inhibition in both cortex and
thalamus (Ching et al., 2010). The hypersynchronous alpha oscilla-
tions persist as long as propofol is continuously infused (Purdon
et al., 2013). The slow oscillations also persist yet, unlike the alpha
oscillations, are not spatially coherent, i.e., hypersynchronous
across the scalp (Cimenser et al., 2011; Lewis et al., 2012; Purdon
et al., 2013). The mechanism of the slow oscillations during propo-
fol maintenance is likely identical to the one for the bolus admin-
istration. Given that sevoﬂurane and propofol both act primarily at
GABAergic circuits, the mechanisms for the alpha and slow-delta
oscillations for sevoﬂurane are likely similar to those for propofol
(Hemmings et al., 2005; Lewis et al., 2012; Purdon et al., 2013;
Akeju et al., 2014).
Administration of dexmedetomidine to maintain deep sedation
is also associated with EEG slow-wave oscillations (Akeju et al.,
2014). This is because dexmedetomidine acts pre-synaptically to
block release of norepinephrine from adrenergic nerve terminals
projecting from the locus coeruleus (Correa-Sales et al., 1992;
Jorm and Stamford, 1993; Chiu et al., 1995; Mizobe et al., 1996;
Nelson et al., 2002; Saper et al., 2005). These nerves terminate dif-
fusely in the cortex, in the intralaminar nucleus of the thalamus, in
the basal forebrain and in the pre-optic area of the hypothalamus
(Brown et al., 2010, 2011). The mechanism of action of
K.J. Pavone et al. / Clinical Neurophysiology 127 (2016) 556–564 563dexmedetomidine suggests that reduced cortical inputs achieved
by inactivating one of the principal arousal pathways can result
in EEG slow oscillations. Inactivation of dopaminergic centers can
also result in EEG slow waves. In rats, lesions in the ventral
tegmental area, the origin of the dopaminergic mesocortical path-
way, produced EEG slow waves and a profound state of decreased
arousal (Jones et al., 1973). Direct injection of sodium thiopental
into the brainstem of rats induced slow-delta oscillations and loss
of consciousness (Devor and Zalkind, 2001) most likely by enhanc-
ing activity in GABAergic projections onto the major brainstem
arousal centers (Brown et al., 2010, 2011).
If our hypothesis is correct, then nitrous oxide-mediated block-
ade of brainstem glutamatergic inputs to the thalamus and cortex
would be another mechanism through which a decrease in brain-
stem excitatory inputs to the cortex leads to slow-delta oscilla-
tions. The neurophysiology of why decreases in major brainstem
inputs to cortical and thalamic circuits favor the production of
slow-delta oscillations which likely reﬂect cortical up-down states,
remains an open question (Crunelli and Hughes, 2010).
4.3. Use of anesthetics to uncover fundamental brain mechanisms
Our ﬁndings regarding nitrous oxide and slow-delta oscillations
contribute to the growing body of work using anesthetics to
uncover fundamental mechanisms of normal and pathological
brain states. Several groups have used studies of general anesthesia
to offer insights into mechanisms of consciousness and altered
states of consciousness (Mashour, 2006; Alkire et al., 2008;
Breshears et al., 2010; Hudetz, 2012; Casali et al., 2013;
Mhuircheartaigh et al., 2013; Monti et al., 2013). Administration
of ketamine has long served as a model for schizophrenia (Olney
and Farber, 1995; Moghaddam et al., 1997), and more recently in
low doses, as a novel immediate therapy for chronic depression
(Zarate et al., 2006). Burst suppression, the profound state of brain
inactivation and unconsciousness manifest in the EEG as periods of
quiescence interspersed with periods of burst-like electrical
activity, is associated with coma, developmental brain disorders
and hypothermia yet, can be readily induced by administration
of anesthetics (Amzica, 2009; Lewis et al., 2013). Studies of
anesthetic-induced burst suppression are providing new ideas
regarding the mechanisms that underlie this brain state that can
be produced by many seemingly different phenomena (Amzica,
2009; Ching et al., 2012; Liley and Walsh, 2013). In addition, con-
trolled anesthetic-induced burst suppression is the approach used
to achieve a medically-induced coma as treatment for intractable
seizures or intracranial hypertension following a brain injury
(Hunter and Young, 2012; Ching et al., 2013; Shanechi et al.,
2013). Both propofol-induced unconsciousness and alpha coma
are associated with large alpha oscillations suggesting that uncon-
sciousness under propofol-induced general anesthesia may help
unravel the pathophysiology and poor prognosis of alpha coma
(Cimenser et al., 2011; Sutter and Kaplan, 2012; Purdon et al.,
2013). Finally, dexmedetomidine provides a pharmacological
model for studying sleep mechanisms (Nelson et al., 2003;
Huupponen et al., 2008; Akeju et al., 2014). Low-dose dexmedeto-
midine induces slow-wave oscillations and spindles (9–15 Hz
oscillations) similar to those seen in non-REM stage II sleep,
whereas higher doses of this sedative produce slow-wave oscilla-
tions similar to those found in non-REM stage III (slow-wave) sleep
(Huupponen et al., 2008; Akeju et al., 2014).
4.4. Future directions and clinical implications
This is a retrospective report. Therefore, our observations
should be conﬁrmed in a prospective investigation that allows pre-
cise anesthetic delivery, and thereby, relates more directly the timecourse of the nitrous oxide dosing and the EEG changes. It will also
be important to include a behavioral paradigm to deﬁne clearly the
level of consciousness during the nitrous oxide-induced slow
oscillations (Purdon et al., 2013). Are the nitrous oxide slow-delta
oscillations a marker of profound unconscious, as in the case of
slow oscillations due to bolus administration of propofol? Or, are
these oscillations a marker of a sedative state from which a patient
can be readily aroused as in the case of dexmedetomidine sedation
(Akeju et al., 2014)? Conducting a prospective study with a larger
cohort of patients or study subjects will allow us to understand
better the between-subject variation in time of onset and duration
of slow-delta oscillations induced by nitrous oxide.
As reported by Hagihira and colleagues, we have also observed
that switching to nitrous oxide from isoﬂurane also produces
slow-delta oscillations (Hagihira et al., 2012). We have observed
a similar EEG dynamics in the transition from the ether anesthetic,
desﬂurane and from propofol. It will be beneﬁcial to study
prospectively the slow-delta oscillatory dynamics induced by the
transition from these anesthetics as well. The transition to nitrous
oxide from an ether anesthetic differs from the transition from
propofol. High-ﬂow delivery of nitrous oxide with oxygen and air
facilitates emergence from an inhaled ether anesthetic by changing
the ﬂow gradients whereas switching from propofol, an intra-
venous anesthetic, produces no such change. Finally, if our
NMDA-glutamatergic hypothesis is correct, then lesion, local phar-
macological inhibition and/or optogenetic inactivation of gluta-
matergic circuits in the parabrachial nucleus and/or the medial
pontine reticular formation should result in slow-delta oscillations
and decreased arousal.
In summary, slow-delta oscillations can be produced by admin-
istering high-dose nitrous oxide. Further study of these oscillations
should offer new insights into the neural circuit mechanisms of
nitrous oxide and make possible more informed use of this agent
during management of general anesthesia. These studies will also
provide deeper insights into the neurophysiology of the brain’s
arousal circuitry.Acknowledgements
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